Hugo: CASP9 Other names: APAF-3; ICE-LAP6; MCH6 Location: 1p36.2
Transcription
Three mRNA isoforms have been identified in Homo sapiens. Caspase-9S, also classified as caspase-9b or caspase9beta, is a small variant of caspase-9 lacking exons 3-6, which contain the catalytic domain. Caspase-9S functions as an endogenous dominant-negative isoform of full-length caspase-9 by binding to the Apaf-1 protein thus hampering its binding and processing of the full-length procaspase-9. Recently, it has been cloned and characterized a novel caspase-9 splice variant, named caspase9-gamma. Caspase9-gamma is generated from an alternative splicing of the fourth exon of caspase-9 gene that results in a 58 nucleotide-long insertion, absent in caspase-9 full length. As the inserted fragment introduces a stop codon, the resulting RNA sequence is prematurely terminated and translated in a 154 aminoacids protein corresponding to only the CARD domain of the caspase-9 full length. Caspase9-gamma does not contain small and large catalytic subunits and cannot promote apoptosis, but like caspase-S, it can function as an apoptosis inhibitor by interferring with the CARD-CARD interaction between procaspase-9 and Apaf-1.
Protein

Description
Like for other caspase genes, caspase-9 mRNA is translated in a precursor protein, the procaspase, that is subsequently converted to the active enzyme. The procaspase-9 consists of 416 amino acids corresponding to a molecular weight of 46281 Da. Cleavages at Asp315 and Asp330 by granzyme B and CPP32 ( caspase-3 ), respectively, generate two active peptides. The active caspase-9 is, in fact, constituted by an heterodimer of a 35kDa (p35) and a 10 kDa (p10) subunit. It belongs to the peptidase C14 family and contains three major domains: a prodomain (in which a CARD domain is located), a large subunit catalytic domain (LSCD) and a small subunit catalytic domain (SSCD).
Expression
Caspase-9 expression is ubiquitous, with highest expression in the heart and a moderate expression in liver, skeletal muscle, and pancreas.
Localisation
Mainly cytosolic, but both proenzyme and active caspase-9 have been also observed in the mitochondria and in the nucleus.
Function
Caspase-9 is a member of the cysteine aspartic acid protease, or caspase, family. The procaspase-9 is activated in apoptotic conditions and it is involved in the activation of the caspase cascade responsible for apoptosis execution. The procaspase-9 and Apaf-1 interact each other through their CARD domains generating, in presence of cytochrome c and ATP, the protein complex named 'apoptosome'. The latter one, in turn, cleaves and activates the effector caspases such the caspase-3. Caspase-9 plays an essential role in apoptosis during normal development. The majority of homozygous CASP-9 null mice die perinatally with an enlarged and malformed cerebrum caused by a reduced apoptosis during brain development. 
Homology
Mutations
Germinal
Not known in Homo sapiens.
Somatic
Three different somatic mutations have been detected in two colorectal carcinomas and in one gastric carcinoma among 353 cancer specimen analyzed, including 180 gastric, 104 colorectal and 69 lung adenocarcinomas. However, all these mutations were silent mutation, thus not contributing to the pathogenesis of these cancers.
Implicated in
Lung cancer
Cytogenetics CASP-9 promoter polymorphisms influence the promoter activity and are associated with the risk of developing lung cancer. Oncogenesis It has been examined the association of four CASP-9 promoter polymorphisms with the risk of lung cancer in a Korean population comprising 432 lung cancer patients and 432 healthy controls. The -1263 GG genotype was associated with a significantly decreased risk of lung cancer compared with -1263 AA or combined -1263 AA + AG. Moreover, individuals with at least one -712T allele had a significantly increased risk of lung cancer compared with those carrying the -712 CC genotype. In brief, the polymorphisms that result in an higher promoter activity seem to be associated with a decreased risk to develop lung cancer. Polymorphisms in CASP-9 promoter can then be useful markers for determining genetic susceptibility to this cancer. However, the association between CASP-9 polymorphisms and risk of lung cancer seem to be influenced by tobacco smoking, no association being present in never-smoker patients. Moreover, as polymorphisms can show ethnic variations, the observations should be extended to diverse ethnic groups. Disease Colon cancer. Oncogenesis Caspase-9 was shown to be downregulated in colon cancer samples in comparison with normal mucosa tissues. Immunohistochemical analysis reveals that the expression of caspase-9 is variable in the healthy enterocytes. However, in the enterocytic component of 12 among 26 cancer samples analyzed, a decrease in caspase-9 immunostaining intensity has been observed: a profile similar, but to a smaller extent, to that observed for caspase 7.
Head and neck squamous cell carcinoma
Oncogenesis
In a certain type of head and neck squamous cell carcinoma cells (HNSCCs), the inhibition of caspase-9 activity and Apaf-1 expression may represent a mechanism of acquired cisplatin resistance. It has been reported that cisplatin induced caspase-9 activation and apoptosis in cisplatin-sensitive HNSCCs in vitro. On the contrary, the cisplatin-resistant HNSCCs analyzed were not able to activate caspase-9 following cisplatin treatment, thus not responding to the therapy.
Testicular germ cell cancer
Oncogenesis
Similarly to head and neck squamous cell carcinama cells, failure of activation of caspase-9 induces cisplatin resistance in testicular cancer cells in vitro. Testicular germ cell cancer is a tumor highly responsive to cisplatin-based chemotherpy, but in a few cases a phenomenon of chemoresistence can occour leading to an unfavourable prognosis. In in vitro experiments, it has been shown that a cisplatin-resistant human testicular germ cell cancer cell line (1411HP) failed to activate caspase-9 and apoptosis after cisplatin treatment in comparison with two cisplatin-sensitive human testicular germ cell cancer cell line (2102EP and H12.1). In the resistant cell line, however, it was possible induce a caspase-9 independent apoptosis using a 3.3-fold higher cisplatin dose.
Nodal diffuse large B-cell lymphoma
Oncogenesis By using biopsy specimens of primary diffuse large Bcell lymphoma (DLBCL) it has been demonstrated that a cellular profile consistent with inhibition of the caspase-9 pathway is associated with poor response to chemotherapy and fatal outcome. On the contrary, a cellular profile consistent with caspase-8 pathway inhibition is associated with an excellent response to chemotherapy. Identifying the functional status of caspase-9 and caspase-8 in patients may have implications for the outcome prediction and for development of alternative therapeutics strategies.
Gastric cancer
Oncogenesis Seven cell lines derived from human gastric cancers were used to investigate the involvement of caspases in chemoresistance mechanisms. Among those examined, the cell line most resistant to apoptotic stimuli expressed the highest levels of the caspase-9 isoform beta, thus confirming the role of caspase-9 in promoting apoptosis in treated cancer cells.
To be noted
Note: Caspase-9 molecular manipulation could be useful for T-cell therapy and for antiangiogenic gene therapy. It has been observed that the local delivery of an inducible caspase-9 resulted in endothelial cell apoptosis and local ablation of vicrovessels in a mouse model of human angiogenesis. Adenoviral vectors containing inducible forms of caspase-9 could be used as antiangiogenic drugs for treatment of angiogenesisdependent diseases, as, in example, cancer.
